The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.
Richard Finn
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Onyx
Honoraria - Genentech
Research Funding - Pfizer
Katalin Boer
No relevant relationships to disclose
Istvan Lang
No relevant relationships to disclose
Rupesh Parikh
No relevant relationships to disclose
Ravindranath Patel
No relevant relationships to disclose
Marcus Schmidt
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Christopher Hagenstad
Research Funding - Pfizer
Howard Lim
Research Funding - Pfizer
Tamas Pinter
No relevant relationships to disclose
Dino Amadori
No relevant relationships to disclose
David Chan
No relevant relationships to disclose
Robert Dichmann
No relevant relationships to disclose
Sindy Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Sophia Randolph
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Dennis Slamon
No relevant relationships to disclose
John Crown
Honoraria - Pfizer
Research Funding - Pfizer
Other Remuneration - Pfizer